CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy

Adoptive cell therapy with chimeric antigen receptor (CAR) immunotherapy has made tremendous progress with five CAR T therapies approved by the US Food and Drug Administration for hematological malignancies. However, CAR immunotherapy in solid tumors lags significantly behind. Some of the major hurd...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Kevin, Farrukh, Hizra, Chittepu, Veera Chandra Sekhar Reddy, Xu, Huihong, Pan, Chong-xian, Zhu, Zheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8969382/
https://www.ncbi.nlm.nih.gov/pubmed/35361234
http://dx.doi.org/10.1186/s13046-022-02327-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8969382/
https://www.ncbi.nlm.nih.gov/pubmed/35361234
http://dx.doi.org/10.1186/s13046-022-02327-z

Ejemplares similares